Biocon Biologics set to reap Biosimilar Insulin Glargine Opportunity in US
Summary : Drugmaker is banking on the ramp-up of interchangeable biosimilar insulin glargine expecting the product to boost the revenue and profit…
Summary : Drugmaker is banking on the ramp-up of interchangeable biosimilar insulin glargine expecting the product to boost the revenue and profit…
Summary : -Biocon Biologics Ltd, said its partner Viatris has won favourable decisions from a US federal court in Sanofi’s challenge over…
Summary: In a split decision, the U.S. Court of Appeals for the Federal Circuit affirmed a West Virginia federal court’s ruling that…